Choate Investment Advisors Has $2.33 Million Position in IQVIA Holdings Inc. $IQV

Choate Investment Advisors boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 837.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 10,354 shares of the medical research company’s stock after buying an additional 9,250 shares during the quarter. Choate Investment Advisors’ holdings in IQVIA were worth $2,334,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ameliora Wealth Management Ltd. acquired a new position in IQVIA during the 4th quarter worth about $25,000. Physician Wealth Advisors Inc. lifted its holdings in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after buying an additional 134 shares during the period. International Assets Investment Management LLC acquired a new position in IQVIA during the 4th quarter worth about $27,000. Westside Investment Management Inc. lifted its holdings in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the period. Finally, Measured Wealth Private Client Group LLC acquired a new position in IQVIA during the 3rd quarter worth about $30,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQVIA stock opened at $168.28 on Tuesday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The firm has a market capitalization of $28.09 billion, a price-to-earnings ratio of 20.85, a PEG ratio of 1.61 and a beta of 1.18. The business has a 50-day simple moving average of $169.83 and a 200 day simple moving average of $197.14. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has approved a share repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research analysts have commented on IQV shares. Stifel Nicolaus cut their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. UBS Group decreased their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Mizuho set a $215.00 target price on IQVIA in a research note on Monday, February 23rd. Evercore reaffirmed an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Finally, BMO Capital Markets set a $250.00 target price on IQVIA in a research note on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $225.69.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.